Clinical Pharmacology and Therapeutics
-
Publication Venue For
-
Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
2020
-
Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality..
103:202-205.
2018
-
Improving the tools of clinical pharmacology: Goals for 2017 and beyond..
101:22-24.
2017
-
Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision..
99:169-171.
2016
-
Improving evidence developed from population-level experience with targeted agents..
97:478-487.
2015
-
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety.
96:704-712.
2014
-
Career Profile.
96:411-411.
2014
-
Human endotoxin administration as an experimental model in drug development..
96:418-422.
2014
-
Phenotype standardization for statin-induced myotoxicity.
96:470-476.
2014
-
Improving the assessment of heart toxicity for all new drugs through translational regulatory science..
95:501-508.
2014
-
Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics.
94:525-532.
2013
-
Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: challenges in comparative effectiveness using Medicare data..
89:674-682.
2011
-
The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration..
87:539-542.
2010
-
Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure.
88:548-554.
2010
-
Benefits exceed risks of newer antidepressant medications in youth--maybe..
86:355-357.
2009
-
The clinical utility index as a practical multiattribute approach to drug development decisions..
86:105-108.
2009
-
Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake..
85:362-365.
2009
-
Racial Differences in Blood Pressure Response toAngiotensin-Converting Enzyme Inhibitors in Children: A Meta-Analysis (vol 84, pg 315, 2008).
84:636-636.
2008
-
The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software..
84:448-456.
2008
-
Corrigendum: Editorial (Clinical Pharmacology Therapeutics (2008) 84, (3-6) DOI: 10.1038/clpt.2008.99).
84:430.
2008
-
Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10).
84:430.
2008
-
Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin.
83:416-421.
2008
-
Erratum: Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: A meta-analysis (Clinical Pharmacology Therapeutics (2008) 84, (315-319)).
84:636-.
2008
-
Should the patent system for new medicines be abolished?.
82:488-490.
2007
-
Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy..
82:435-440.
2007
-
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa.
82:197-203.
2007
-
Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics..
82:118-121.
2007
-
"Personalized medicine: elusive dream or imminent reality?": A commentary..
81:801-805.
2007
-
Medical Product Development and Regulatory Science for the 21st Century: The Critical Path Vision and Its Impact on Health Care.
81:141-144.
2007
-
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests..
78:559-581.
2005
-
American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation..
77:113-122.
2005
-
Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships..
74:569-580.
2003
-
PK of buprenorphine transdermal system (BTDS 10) employing the LPS pyrogen model.
69.
2001
-
Regulating manufacturer-affiliated communication in the information age..
65:593-597.
1999
-
Antipyretic effect of celecoxib (C) in endotoxin induced fever.
65:172.
1999
-
Single and multiple dose pharmacokinetics of transdermal buspirone in subjects with hepatic cirrhosis compared to healthy subjects.
65:168.
1999
-
Stereoselective monitoring of ± verapamil treatment of women with bipolar disorder.
65:158.
1999
-
Benzodiazepine use and cognitive function among community-dwelling elderly..
64:684-692.
1998
-
Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty..
63:232-232.
1998
-
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.
61:205.
1997
-
Effects of oxaprozin (OXA) on enalapril (EN) and enalaprilat (ET) pharmacokinetics (PK), pharmacodynamics (PD): Blood pressure (BP), heart rate (HR), plasma renin activity (PRA), aldosterone (AL) and creatinine clearances (CLcr), in hypertensive patients (HP).
61:208.
1997
-
Effects of oxaprozin (OXA) on platelet function (PF) in healthy male subjects (Ss).
61:204.
1997
-
Bidirectional interaction of valproate and lamotrigine in healthy subjects..
60:145-156.
1996
-
Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.
59:PI84-PI84.
1996
-
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone..
56:86-99.
1994
-
Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects..
55:55-63.
1994
-
Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers..
54:670-679.
1993
-
Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients..
52:597-604.
1992
-
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem..
51:562-565.
1992
-
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics..
51:371-378.
1992
-
Differential response of beta-adrenergic receptor-mediated heart rate and aortic blood flow acceleration to timolol..
51:296-301.
1992
-
PHARMACOKINETICS (PK) OF L-OFLOXACIN IN HIV-INFECTED PATIENTS.
51:182-182.
1992
-
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol..
51:18-23.
1992
-
New drug application strategies for supraventricular arrhythmias..
49:481-487.
1991
-
A COMPARISON OF PAIN, SEDATION, AND RESPIRATORY DEPRESSION FOLLOWING PENTAMORPHONE OR FENTANYL GENERAL-ANESTHESIA.
49:182-182.
1991
-
Pharmacodynamics of propranolol on left ventricular function: assessment by Doppler echocardiography..
48:431-438.
1990
-
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril..
48:447-454.
1990
-
Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options..
48:111-119.
1990
-
Transdermal nicotine facilitates smoking cessation..
47:323-330.
1990
-
NICARDIPINE VS SODIUM-NITROPRUSSIDE FOR TREATMENT OF POSTOPERATIVE HYPERTENSION.
47:198-198.
1990
-
Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients..
46:234-239.
1989
-
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension..
46:208-218.
1989
-
Erratum: Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients (Clin Pharmacol Ther 1989; 46: 234-9).
46:500.
1989
-
Oral dipyridamole increases plasma adenosine levels in human beings..
45:80-84.
1989
-
Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin..
44:78-92.
1988
-
Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension..
43:429-435.
1988
-
Chronic effects of nitrendipine on renal hemodynamics and tubular transport..
43:6-15.
1988
-
Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations..
39:25-28.
1986
-
Transdermal nicotine reduces cigarette craving and nicotine preference..
38:450-456.
1985
-
Tocainide kinetics in congestive heart failure..
34:596-603.
1983
-
Hemodynamic effects of the antiarrhythmic drug pirmenol..
32:235-239.
1982
-
Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction..
30:154-157.
1981
-
'Free lidocaine index' as a guide to unbound drug concentration.
29:282-283.
1981
-
A double-blind comparative study of the antihypertensive effectiveness of once-vs twice-daily dosing of methyldopa/hydrochlorothiazide in hypertensive patients.
29:269-270.
1981
-
Factors affecting lidocaine disposition.
29:283.
1981
-
Length of time required for effective antihypertensive therapy to reduce left ventricular hypertrophy.
29:258-259.
1981
-
Therapeutic monitoring of lidocaine concentrations.
29:284.
1981
-
Clonidine-chlorthalidone combination once and twice daily in essential hypertension..
28:581-586.
1980
-
Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney..
28:680-689.
1980
-
Absorption of nicotine from small cigars.
23:143-151.
1978
-
Nonemergency use of slow infusions of diazoxide.
18:154-157.
1975
-
Monoamine precursors in the treatment of depression..
12:743-761.
1971
-
The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man.
11:3-40.
1970
-
Laboratory and clinical studies of penicillin X-1497..
2:70-79.
1961
-
Effect of certain drugs on the incidence of seasickness.
1:280-283.
1960
-
CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
2020
-
CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
2020
-
EVALUATION OF A PEDIATRIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR SOLITHROMYCIN USING PLASMA AND DRIED BLOOD SPOTS (DBS) DRUG CONCENTRATIONS.
2020
-
EVALUATION OF A PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SOLITHROMYCIN USING PLASMA AND DRIED BLOOD SPOTS (DBS) DRUG CONCENTRATIONS.
2020
-
EXTERNAL EVALUATION OF POPULATION PHARMACOKINETIC (PPK) MODELS OF TRIMETHOPRIM (TMP) AND SULFAMETHOXAZOLE (SMX) DEVELOPED USING OPPORTUNISTIC DATA IN INFANTS AND CHILDREN.
2020
-
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF MEROPENEM IN PRETERM AND TERM INFANTS.
2020
-
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF MEROPENEM IN PRETERM AND TERM INFANTS.
2020
-
METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY.
2019
-
METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY.
2019
-
METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER.
2019
-
METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER.
2019
-
POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.
2019
-
SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ ESCITALOPRAM EXPOSURE.
2019
-
SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ESCITALOPRAM EXPOSURE.
2019
-
DOSE-RELATED INFLAMMATORY EFFECTS OF INTRAVENOUS ENDOTOXIN IN HUMANS: EVALUATION OF A NEW CLINICAL LOT (CCRE LOT 94332B1) OF ESCHERICHIA COLIO: 113 ENDOTOXIN (LPS).
2018
-
INTRA-TARGET MICRODOSING (ITM), A NOVEL DRUG DEVELOPMENT APPROACH: PROOF-OF-CONCEPT IN HUMANS
2017
-
LEAN BODY WEIGHT (LBW) DOSING OF PANTOPRAZOLE IS APPROPRIATE FOR OBESE CHILDREN.
2017
-
SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE
2017
-
A METFORMIN METABOLOMIC EXPRESSION PROFILE STUDY UTILIZING AN ELECTRONIC HEALTH RECORD (EHR)-LINKED BIOREPOSITORY AND INTEGRATIVE MOLECULAR EPIDEMIOLOGY APPROACHES
2016
-
ANTIFUNGAL EXTRACTION BY THE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) CIRCUIT EX VIVO.
2015
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
DIFFERING SIROLIMUS-INDUCED HYPERLIPIDEMIA AND RESPONSE TO STATIN THERAPY BETWEEN CYP3A5 EXPRESSERS AND NON-EXPRESSERS IN KIDNEY TRANSPLANTATION.
2009
-
USE OF MONTE CARLO SIMULATION (MCS) TO EVALUATE TOXICITY AND EFFICACY BREAKPOINTS OF A NOVEL ANTIBIOTIC
2009